Several new beta-lactam antimicrobial agents have been introduced in the last few years. In this investigation, the in vitro activities of several recently introduced cephalosporins (cefoperazone, cefotaxime, ceftazidime, and ceftizoxime), moxalactam, and N-formimidoyl thienamycin were compared with those of cefoxitin, clindamycin, and metronidazole against 203 strains of anaerobic bacteria. At achievable serum levels, all of the antimicrobial agents were active against essentially 100% of the strains of anaerobic gram-positive cocci, Clostridium perfringens, Leptotrichia buccalis, and species of Selenomonas, Veillonella, and Eubacterium. Clindamycin, metronidazole, and N-formimidoyl thienamycin were the most active agents against the Bacteroides fragilis group, inhibiting all strains at concentrations which can be achieved in serum. Of the remaining agents tested against the B. fragilis group, cefoxitin (which required 64 ,tg/ml to inhibit 90% of the strains) was the most active, followed by cefoperazone (128 ,ug/ml), cefotaxime (128 ,tg/ml), moxalactam (128 ,ug/ml), ceftizoxime (256 ,ug/mi), and ceftazidime (>256 pg/ml). Important differences in cephalosporin susceptibility among species of the B. fragilis group were observed. Metronidazole and N-formimidoyl thienamycin were the most active drugs against species of clostridia other than C. perfringens; the other antibiotics displayed poor activity, although this is partly due to inclusion of a relatively large number of strains of Clostridium difficile which were very resistant to several of the cephalosporins. Only metronidazole was active against all species of Fusobacterium. Clindamycin and N-formimidoyl thienamycin displayed excellent activity against gram-positive, non-spore-forming bacilli, requiring c8 ytg/ml to inhibit 100% of the strains. Ceftazidime, cefoperazone, and moxalactam were bactericidal for 25 strains of B. fragilis at concentrations equal or close to those required for inhibition. On the basis of its activity in vitro, N-formimidoyl thienamycin appears to be the most promising of the new beta-lactam antibiotics for the treatment of infections involving anaerobic bacteria.
(128 ,tg/ml), moxalactam (128 ,ug/ml), ceftizoxime (256 ,ug/mi), and ceftazidime (>256 pg/ml). Important differences in cephalosporin susceptibility among species of the B. fragilis group were observed. Metronidazole and N-formimidoyl thienamycin were the most active drugs against species of clostridia other than C. perfringens; the other antibiotics displayed poor activity, although this is partly due to inclusion of a relatively large number of strains of Clostridium difficile which were very resistant to several of the cephalosporins. Only metronidazole was active against all species of Fusobacterium. Clindamycin and N-formimidoyl thienamycin displayed excellent activity against gram-positive, non-spore-forming bacilli, requiring c8 ytg/ml to inhibit 100% of the strains. Ceftazidime, cefoperazone, and moxalactam were bactericidal for 25 strains of B. fragilis at concentrations equal or close to those required for inhibition. On the basis of its activity in vitro, N-formimidoyl thienamycin appears to be the most promising of the new beta-lactam antibiotics for the treatment of infections involving anaerobic bacteria.
Several new beta-lactam antibiotics have been introduced in the last few years. Several recently introduced cephalosporins, including ceftizoxime, cefoperazone, cefotaxime, and ceftazidime, are distinguished from earlier cephalosporins by increased resistance to beta-lactamase degradation and extended antibacterial spectrum. N-formimidoyl thienamycin, a stable derivative of thienamycin, and moxalactam are beta-lactam antibiotics with potent and broad-spectrum activities.
The purpose of the present study was to examine the in vitro activity of these new compounds against various strains of anaerobic bacteria. Using an agar dilution technique, the ac- (27) . The minimal bactericidal concentration (MBC) was read as the lowest concentration of antimicrobial agent that resulted in >99% killing of the organims in the original inoculum after 48 h of incubation at 37°C. Table 1 summarizes susceptibility data on those species/genera represented by six or more isolates in terms of the concentration of drug required to inhibit 50% (MIC5o) and 90% (MlCso) of the strains and the range of MICs. Susceptibilities of the remainder of the strains examined in this investigation are summarized in Table 2 . The percentages of strains inhibited at achievable concentrations of each antimicrobial agent in serum are shown in Table 3 . Achievable serum levels were considered to be the concentrations that could be attained 30 to 60 min after administration of mimal safe dosages. These levels were based on information supplied by the manufacturers (cefotaxime, thienamycin, ceftizoxime, and ceftazidime) and criteria used by Finegold (9) and Kirby et al. (18) .
RESULTS
At achievable serum levels, all of the antimicrobial agents examined were active against essentially 100% of the strains of anaerobic grampositive cocci, Clostridium perfringens, Selenomonas species, Veillonella species, Eubacterium species, and Leptotrichia buccalis. The exception was one strain ofPeptococcus magnus which was resistant to ceftazidime (MIC, 64 ug/ ml (MIC, 128 ,ug/ml), and both strains of Fusobacterium mortiferum were resistant to ceftizoxime, cefotaxime, and ceftazidime (MIC, >256 ,u/ml).
Metronidazole and N-formimidoyl thienamycin were the most active compounds against species of clostridia other than C. perfringens.
Concentrations of 0.125 to 16 Mg/ml of these two antimicrobial agents were required to inhibit these microorganisms. Several strains of Clostridium difficile were resistant to all of the betalactam antibiotics and clindamycin.
Clindamycin and N-formimidoyl thienamycin displayed excellent activity against gram-positive non-spore-forming bacilli, requiring c8 Mg! ml to inhibit 100% of the strains. On the other hand, the two strains of Eubacterium lentum were resistant to cefoperazone (MIC, -64,g/ ml), cefotaxime (MIC; 64 4g/ml), ceftazidime (MIC, >256,ug/ml), and moxalactam (MIC, 128 ,ug/ml). One strain each of Actinomyces odontolyticus (MIC, >256 ,ug/ml) and Actinomyces species group I (MIC, 64 ,ug/ml) were resistant to metronidazole. The one strain of Bifidobacterium species examined in this investigation was resistant to cefoperazone (MIC, 64 ,ug/ml), cefoxitin (MIC, 128,ug/ml) ceftazidime (MIC, 64 ,ug/ml) and moxalactam (MIC, 128,ug/ml). The Lactobacillus species was resistant to moxalactam (MIC, 64 ,ug/ml), cefoperazone (MIC, 128 ,ug/ml), cefotaxime (MIC, 128 ,ug/ml), ceftizoxime (MIC, 128 yg/ml), and ceftazidime (MIC, >256,g/ml).
Ceftazidime, cefoperazone, and moxalactam were bactericidal for 25 strains of B. fragilis (Fig. 1) . The MICs and MBCs of these three agents against all strains were identical or one tube (twofold dilution) apart. DISCUSSION
The comparative in vitro inhibitory activities of recently developed beta-lactam antibiotics against anaerobic bacteria has not been studied extensively. Cefoperazone, cefotaxime, ceftizoxime, and ceftazidime are recently introduced cephalosporins which differ from their predecessors, such as cefoxitin, by alterations of the basic cephalosporin nucleus and its substituent groups. These new cephalosporins have been reported to have broader spectrum of activity than older agents and relative resistance to hydrolysis by beta-lactamases (10, 16, 20, 26) . In this investigation, cefoxitin, a beta-lactamase-resistant cephamycin, was level. The antibacterial activity of cefoxitin in the present study is generally consistent with the findings of others (17, 20, 30, 31) . Some investigators, however, have found cefotaxime and moxalactam to be more active than cefoxitin against anaerobic bacteria, particularly against species of Bacteroides other than B. fragilis (2, 4, 14, 16, 19, 35) . The failure of moxalactam to yield distinct endpoints of growth in this investigation, the use of different methodologies, and regional differences in susceptibility may explain the reported discrepancies in the activity ofmoxalactam against anaerobic bacteria.
The 28, 32, 34) . This is in contrast to clindamycin, which is not always bactericidal (34) .
In this investigation, B. distasonis, B. thetaiotaomicron, and B. ovatus were found to be distinctly more resistant to cefoperazone, ceftizoxime, ceftazidime, and moxalactam than the other two members of the B. fragilis group. In view of the difference in the susceptibility of these microorganisms to various antimicrobial agents, speciation of the members of the B. fragilis group is now desirable.
The resistance of a number of species of Bacteroides to cephalosporins has been ascribed to the production of beta-lactamases (1, 5, 24, 33, 36, 37) . This enzyme has been shown to be membrane associated, constitutively produced, and present in all strains of Bacteroides which are resistant to cephalosporins (33) . Experiments with clavulanic acid, a beta-lactamase inhibitor, suggest that more than one type of beta-lactamase may be produced by Bacteroides species (25) . The beta-lactamases of B. fragilis have been shown to be most active against cephalosporins and virtually inactive against cefoxitin and thienamycin (5, 6, 21, 25, 33) . Several investigators have suggested that the increased activity of the new cephalosporins against anaerobic bacteria and, in particular, members of the B. fragilis group, is due to their stability to a wide range of bacterial beta-lactamase enzymes (7, 10, 20) . The results of our study suggest that the third generation cephalosporins, even with their reported greater stability to beta-lactamases, may still be susceptible to the betalactamase activity of the B. fragilis group. In addition to beta-lactamase production, there are undoubtedly other factors which may contribute to the resistance of Bacteroides species to cephalosporins (e.g., diffusion barrier to beta-lactam antibiotics).
With the exception of cefoperazone, which inhibited 70% of the Clostridium species other than C. perfringens at 32 ,ug/ml, the cephalosporins displayed very poor activity against this group of organisms. In particular, C. difficile proved rather resistant to the new cephalosporins; this skewed the overall data on clostridia other than C. perfringens since half of these strains were C. difficile. However, resistance is still relatively common with the other species. Not enough information is available to determine the extent to which the new betalactam antibiotics will induce intestinal diseases associated with toxigenic C. difficile.
The data obtained in this investigation suggest that, except for N-formimidoyl thienamycin, the newest beta-lactam antibiotics may be of limited value in the treatment of serious infections involving anaerobic bacteria. For example, these agents were inactive against at least 25% of the Our results with clindamycin and metronidazole generally agree with those reported by other investigators (11, 22, 28, 29 The new beta-lactam antibiotic, N-formimidoyl thienamycin, showed impressive in vitro activity against anaerobic bacteria. The overall inhibitory activity of this new compound was somewhat better than that of clindamycin and comparable to that of metronidazole. At 32 ,ug/ ml, N-formimidoyl thienamycin inhibited all strains of anaerobic bacteria examined in this investigation except one Bacteroides species and three strains of F. varium. The activity of Nformimidoyl thienamycin against the B. fragilis group suggests that it is not hydrolyzed by the beta-lactamases of these microorganisms. The excellent in vitro activity of N-formimidoyl thienamycin against essentially all species of anaerobic bacteria, including cefoxitin-resistant bacteroides and clindamycin-and cefoxitin-resistant clostridia, indicates that clinical evaluation of this drug for treatment of anaerobic infections of all types is certainly warranted.
